All In MedTech

FDA Clearance Tracker · P250019-S001

SAPIEN M3 Transcatheter Mitral Valve Replacement System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 19, 2026

Approved

Time to decision

30 days

Received Jan 20, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P250019-S001
Device name
SAPIEN M3 Transcatheter Mitral Valve Replacement System
Applicant location
Irvine, CA
Received
Jan 20, 2026
Decided
Feb 19, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P250019

Device type

Device class
Class III

Every decision under product code NPU

FDA's approval statement

As written in FDA's record.

Approval of the protocols for the post-approval studies, "Continued Follow-up of ENCIRCLE Premarket Cohort" and "Registry-Based Real-World Use Surveillance", submitted to comply with the conditions of approval outlined in the approval order for P250019.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.